Potentiality of Bacteriocins as the Attachment Inhibitors of HIV-1 gp120
Abstrakt
It is postulated that some bacteriocin derivatives are consummate candidates to inhibit the binding of HIV gp120 to CD4 T-cell. From the discovery of bacteriocin compounds in 1925 and forth, nearly 300 bacteriocins have been identified. Of various bacteriocins, there are some which have been used successfully for inhibiting both animal and human pathogens. Unfortunately, no large extent research has been found in the development of various bacteriocins as HIV entry inhibitor. Therefore, we need to initiate to hunt for potential bacteriocins that prevent viral entry to T-cells and protect HIV victims. In this current study, we have proposed the static approach to categorize 177 bacteriocins into several distinguishing molecular descriptor (MD) families according to their structures (amino acid sequences) and inhibition capacity of HIV entry by utilizing the second released database tool of BACTIBASE. This process of classification will reduce our time to search for appropriate bacteriocins with best inhibition capacity of HIV entry. We have proposed the methodologies to test this representative class further in vitro and in silico. The main advantage of bacteriocin compounds is that we are able to design them in various formulations, such as, capsule, tablet, dry powder for suspension, etc., and prescribe them orally like antibiotics. As entry inhibitors (EIs), the potential bacteriocins are suitable ingredients to prepare vaginal/rectal gels, creams, pills and intravaginal ring systems. Not only that, the bacterial strains that produce omnipotent bacteriocins can be used as a human vaginal/rectal/oral probiotic strains which can potentially lower the sexual transmission of HIV. Keywords: Bacteriocin derivatives, HIV entry inhibitors, BACTIBASE, in vitro and in silico test Cite this Article SK. Md. Mujahidy Jakaria. Potentiality of Bacteriocins as the Attachment Inhibitors of HIV-1 gp120. Research & Reviews: Journal of Microbiology and Virology. 2015; 5(3): 18–23p.Publikováno
Číslo
Sekce
Licence
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
· I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
· I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
· I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
· I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
_______________
We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |